PMVP PMV Pharmaceuticals, Inc.: Projected Price to Earnings

As a leader in precision oncology, PMV Pharmaceuticals is tasked with solving the most complex challenges of personalized medicine. This chart, provided by GURU.Markets, illustrates the company's forward P/E ratio reflecting market expectations, while 0.00 serves as the base parameter value. Pipeline risks are mitigated through the development of drugs for various types of cancer, while adhering to strict environmental waste disposal regulations.

PMV Pharmaceuticals Inc. - PMVP Future Price to Earnings Multiple (period 07/04/2022 - 11/15/2026)

Analytical breakdowns for PMV Pharmaceuticals

- stock quotes and analyst forecast:

Stock Price PMV Pharmaceuticals Inc.|PMVP - Analyst Target Range

- company stock capitalization data:

Market Valuation PMV Pharmaceuticals Inc.|PMVP - Total Enterprise Value

- issuer book value statistics:

Accounting Value per Share PMV Pharmaceuticals|PMVP - Accounting Value of Company|Market Cap to Net Assets Ratio pmvpharma.com|PMVP - Aggregate Business Assets

- debt level and financial liquidity data:

- financial results and valuation multiples details:

PMVP - Profit After Payment of Taxes|Projected Future Earnings PMV Pharmaceuticals|PMVP - Market Cap to Earnings|Forward P/E Multiple PMV Pharmaceuticals, Inc.|PMVP - Growth-Adjusted P/E Ratio|Enterprise Value to EBITDA Ratio PMV Pharmaceuticals|PMVP - Income before deduction of interest, taxes and amortization|Net earnings per share for the last 12 months PMV Pharmaceuticals|PMVP - Earnings per share for the last four quarters|Quarterly EPS earnings growth pmvpharma.com|PMVP - Earnings per share increase in current year|Earnings growth forecast for next year PMV Pharmaceuticals

- sales volume and revenue information:

PMVP - Company Total Revenue|Company Projected Revenue PMV Pharma|PMVP - Market Capitalization-to-Revenue Ratio|Forward P/S Multiple PMV Pharma|PMVP - Sales Growth YoY (TTM)

Fundamental valuation:PMV Pharmaceuticals Inc.

PMV Pharmaceuticals' development of unique p53 protein reactivation methods makes the company's forward P/E an indicator of market expectations regarding the monetization of targeted oncology drugs. This chart is calculated as the ratio of the current share price to the projected earnings per share, allowing investors to assess the premium paid for potential business growth in the absence of direct pricing competitors.

Competitor analysis